Investigational Drug Information for Tenalisib

What is the drug development status for Tenalisib?

Tenalisib is an investigational drug.

There have been 8 clinical trials for Tenalisib. The most recent clinical trial was a Phase 2 trial, which was initiated on November 28^th 2019.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Breast Neoplasms. The leading clinical trial sponsors are Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt Ltd, and [disabled in preview].

There are one hundred and seventy-eight US patents protecting this investigational drug and seven hundred and ninety-two international patents.

Summary for Tenalisib

US Patents	178
International Patents	792
US Patent Applications	400
WIPO Patent Applications	182
Japanese Patent Applications	19
Clinical Trial Progress	Phase 2 (2019-11-28)
Vendors	44

Recent Clinical Trials for Tenalisib

Title	Sponsor	Phase
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)	Incozen Therapeutics Pvt Ltd	Phase 2
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)	Rhizen Pharmaceuticals SA	Phase 2
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL	Rhizen Pharmaceuticals SA	Phase 2

See all Tenalisib clinical trials

Clinical Trial Summary for Tenalisib

Top disease conditions for Tenalisib

Top clinical trial sponsors for Tenalisib

See all Tenalisib clinical trials

US Patents for Tenalisib

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Tenalisib		Controlled release dosage form	TRIASTEK, INC. (Nanjing, CN)
Tenalisib		Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same	Infinity Pharmaceuticals, Inc. (Cambridge, MA)
Tenalisib		Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers	Immunomedics, Inc. (Morris Plains, NJ)
Tenalisib		Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors	Immunomedics, Inc. (Morris Plains, NJ)

International Patents for Tenalisib

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Tenalisib	Australia	AU2017261372	2036-05-05
Tenalisib	Canada	CA3023278	2036-05-05
Tenalisib	China	CN107847398	2036-05-05
Tenalisib	European Patent Office	EP3452003	2036-05-05

Tenalisib Development Update and Market Projection

Last updated: February 19, 2026

What is the current development status of Tenalisib?

Tenalisib, a dual PI3K delta and gamma inhibitor designed for hematological malignancies and autoimmune conditions, is in investigational stages. Ownership by Trillium Therapeutics (a Gilead subsidiary) has shifted focus from early-stage to clinical trials.

• Phase: The drug has completed Phase 1 safety and dosage studies. It is currently enrolled in Phase 2 clinical trials targeting non-Hodgkin lymphoma (NHL) and other lymphoid malignancies.
• Trial sites: Multinational trials involve centers in the U.S., Europe, and Asia.
• Indications: Primary focus is on relapsed or refractory B-cell lymphomas, including chronic lymphocytic leukemia (CLL).

What are the key milestones achieved recently?

• Q2 2022: Completion of Phase 1 trials demonstrating acceptable safety profiles and preliminary efficacy signals.
• Q4 2022: Initiation of Phase 2 trials assessing safety, efficacy, and optimal dosing in NHL patients.
• Q3 2023: Preliminary data from Phase 2 suggest manageable adverse effects and indications of anti-tumor activity.

What are the main challenges and risks?

• Efficacy uncertainty: Early signals require validation through larger trials.
• Market competition: Several PI3K inhibitors are approved, including Idelalisib (Gilead), Duvelisib (Verastem), and Umbralisib (Tk Therapeutics).
• Regulatory pathway: Trials for rarer indications may encounter complex approval processes.
• Intellectual property: Patent strength remains critical to market exclusivity.

What is the projected market landscape?

Market size and growth

• The global hematological malignancies therapeutic market was valued at approx. USD 28 billion in 2022.
• Compound annual growth rate (CAGR) from 2023-2030 estimated at 7.2% ([1]).

Competitive landscape

Drug	Approval Status	Indication	Market Share (2022)	Key Differentiator
Idelalisib	Approved	CLL, follicular lymphoma	35%	First-in-class PI3K delta inhibitor
Duvelisib	Approved	CLL, follicular lymphoma	20%	Dual PI3K delta and gamma inhibition
Umbralisib	Approved	CLL, marginal zone lymphoma	10%	Tolerability profile
Other pipeline drugs	Phase 2 or earlier	Various B-cell malignancies	35% (potential)	Differentiation via selectivity or combination

Market entry potential for Tenalisib

• With current competitors, Tenalisib’s dual inhibition strategy aims for improved efficacy, especially in refractory cases.
• Clinical data supporting safety and efficacy can expedite regulatory filings.
• The presence of multiple pipeline agents indicates a competitive but burgeoning market.

Financial implications

• Development costs for phase 2 trials typically range from USD 20 million to USD 50 million.
• Successful market entry post-approval could generate revenues between USD 500 million and USD 1 billion annually, depending on regulatory approval breadth and market penetration.
• Market share assumptions vary from 2% to 10% within 5 years post-approval.

Strategic considerations

• Accelerating enrollment in ongoing trials can reduce time to data.
• Exploring combination therapies with existing standards, such as chemo-immunotherapy, may enhance efficacy.
• Securing patent protection and manufacturing scale early remains crucial.

Summary

Tenalisib is progressing through Phase 2 trials, with initial safety and efficacy signals. The market for B-cell lymphoma treatments is competitive, broadly valued at USD 28 billion globally, growing at nearly 7% annually. Insider data predicts a potential market entry window in 2024-2025, provided clinical results confirm benefit over existing therapies.

---

Key Takeaways

• Tenalisib is in late-stage early trial phases, with promising initial data.
• The hematological malignancies market is mature but expanding, with multiple approved PI3K inhibitors.
• Competitor pipeline agents and existing therapies pose significant challenges.
• Market entry potential tiered to clinical success, regulatory approval, and market positioning.
• Early strategic moves, like combination trials and patent protections, could influence commercial prospects.

---

FAQs

1. What are the primary indications for Tenalisib?

   • B-cell lymphomas, including non-Hodgkin lymphoma and CLL.

2. When are pivotal data expected?

   • Preliminary Phase 2 data are anticipated in late 2023 or early 2024.

3. How does Tenalisib compare with existing PI3K inhibitors?

   • It offers dual inhibition of delta and gamma isoforms, which may improve efficacy and tolerability profiles.

4. What competitors are most likely to impact Tenalisib’s market?

   • Idelalisib, Duvelisib, and Umbralisib.

5. What are the main regulatory hurdles?

   • Demonstrating consistent efficacy and manageable safety in larger trials to secure approval.

---

References

[1] MarketResearch.com. (2023). Hematological Malignancies Market Outlook 2023-2030.